Cancer Vaccines Targeting HER2/neu for Early Breast Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ryu, Woo Sang | - |
dc.contributor.author | Son, Gil Soo | - |
dc.date.accessioned | 2021-09-08T05:01:46Z | - |
dc.date.available | 2021-09-08T05:01:46Z | - |
dc.date.created | 2021-06-11 | - |
dc.date.issued | 2010-03 | - |
dc.identifier.issn | 1738-6756 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/116959 | - |
dc.description.abstract | Recent studies of immune responses to pathogens have identified pathogen-associated molecular patterns recognized by the innate immune system through specialized receptors called toll-like receptors (TLRs). Signaling through these receptors initiates robust immune responses. By exploiting TLR signaling pathways, immunity to tumor-associated antigens may be generated Many tumor-associated antigens are involved in the regulation of tumor phenotype or carcinogenesis. Immune targeting of these antigens may either alter the tumor phenotype, yielding a more treatable tumor, or eradicate early tumor stem cells preventing tumor formation. The oncoprotein HER2/neu, which is often overexpressed in ductal carcinoma in situ (DCIS), may provide such a target. Immune responses directed against HER2/neu may eliminate the disease, make tumors more amenable to anti-estrogen therapy, or prevent escape of hormone-resistant tumor phenotypes. Effective breast cancer prevention in preclinical studies utilizing murine HER2/neu transgenic models has stimulated interest in, and optimism regarding, protective breast cancer vaccines in humans. Induction of anti-HER2/neu T cell (CD4+ and CD8+) and B cell responses has been demonstrated in an ongoing clinical study targeting HER2/neu using a TLR agonist-primed dendritic cell vaccine Moreover, these vaccinations lead to reductions in both HER2/neu expression and extent of DCIS HER2/neu expression and aromatase activity have recently been linked through the intermediary cyclooxygenase 2 (COX-2) This convergence between growth factor and hormone mediated pathways provides additional support for the notion that a significant number of breast cancers may be prevented through effective immune targeting of HER2/neu. As progress is made towards the development of vaccines for breast cancer prevention, the contributions of immune-mediated effecter and inhibitory mechanisms to the pathogenesis of HER2/neu overexpressing breast cancer will need to be better understood. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN BREAST CANCER SOC | - |
dc.subject | TOLL-RECEPTOR FAMILY | - |
dc.subject | METASTATIC BREAST | - |
dc.subject | DENDRITIC CELLS | - |
dc.subject | T-CELLS | - |
dc.subject | MONOCLONAL-ANTIBODY | - |
dc.subject | HER-2/NEU PEPTIDES | - |
dc.subject | NEU PROTOONCOGENE | - |
dc.subject | TRANSGENIC MICE | - |
dc.subject | IN-VIVO | - |
dc.subject | TRASTUZUMAB | - |
dc.title | Cancer Vaccines Targeting HER2/neu for Early Breast Cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Son, Gil Soo | - |
dc.identifier.doi | 10.4048/jbc.2010.13.1.5 | - |
dc.identifier.scopusid | 2-s2.0-77953214770 | - |
dc.identifier.wosid | 000276320700002 | - |
dc.identifier.bibliographicCitation | JOURNAL OF BREAST CANCER, v.13, no.1, pp.5 - 13 | - |
dc.relation.isPartOf | JOURNAL OF BREAST CANCER | - |
dc.citation.title | JOURNAL OF BREAST CANCER | - |
dc.citation.volume | 13 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 5 | - |
dc.citation.endPage | 13 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART001435675 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | other | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | TOLL-RECEPTOR FAMILY | - |
dc.subject.keywordPlus | METASTATIC BREAST | - |
dc.subject.keywordPlus | DENDRITIC CELLS | - |
dc.subject.keywordPlus | T-CELLS | - |
dc.subject.keywordPlus | MONOCLONAL-ANTIBODY | - |
dc.subject.keywordPlus | HER-2/NEU PEPTIDES | - |
dc.subject.keywordPlus | NEU PROTOONCOGENE | - |
dc.subject.keywordPlus | TRANSGENIC MICE | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | TRASTUZUMAB | - |
dc.subject.keywordAuthor | Breast neoplasms | - |
dc.subject.keywordAuthor | Dendritic cells | - |
dc.subject.keywordAuthor | HER2/neu | - |
dc.subject.keywordAuthor | Vaccines | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.